News
6h
TipRanks on MSNPfizer and Astellas Pharma’s Promising mCRPC Study Update
Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
The tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment present major challenges to surgeons performing salvage RARP.
Sanders' health issues date back several years, most notably when he had two toes amputated in 2021 due to blood clots. This ...
If confirmed, our findings may provide a more precise clinical target for definitive trials of PA as a prostate cancer treatment as well as for PA promotion efforts in newly diagnosed prostate cancer ...
New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.
ASCO 2025, prostate cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), enzalutamide, 8-Year Outcomes of Enzalutamide Versus a Non-Steroidal Anti-Androgen, ENZAMET trial, ANZUP 1304 trial.
Insights from Arjun Sen, who inspired Shoojit Sircar’s film I Want To Talk, on having a healthy mindset during and after ...
Use of glucagon-like peptide-1 receptor agonists might be beneficial for patients with some cancers, research suggests.
University of Michigan researchers identified a gene program associated with extreme non-response to the cancer drug ...
Cabozantinib plus atezolizumab improved progression-free survival in advanced prostate cancer after ARPI failure.
After Teddi Mellencamp shared her cancer had progressed earlier this year, she shared why she has felt “sicker” amid ...
Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results